052-CAR T-Cell Therapy for Pediatric Central Nervous System

This paper provides an overview of the challenges and advancements in CAR T-cell therapy for pediatric central nervous system (CNS) tumors, which are a leading cause of cancer-related death in children. It discusses the feasibility and early efficacy of CAR T-cell trials, while also highlighting significant obstacles such as limited trafficking to tumors, the immunosuppressive tumor microenvironment, and tumor heterogeneity. The article explores various strategies to overcome these barriers, including optimized delivery methods like locoregional infusion, the identification of suitable tumor targets (e.g., B7-H3, GD2, HER2), and advanced engineering techniques for multi-antigen targeting and enhanced T-cell persistence. Finally, it emphasizes the importance of patient-centered outcomes and equitable access in the future development and implementation of these innovative therapies.

References:

• Timpanaro A, Song E Z, Amwas N, et al. Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors[J]. Cancer Discovery, 2025, 15(5): 890-902.